Faculty
Oncology Division
Alphabetical list (active faculty):   
Daniel Morgensztern

Daniel Morgensztern, MD

Professor

Department of Medicine

Oncology Division

Medical Oncology

Clinical Interests

  • Thoracic malignancies

Research Interests

  • Genomics
  • Immunotherapy
  • Epidemiology
  • Phase 1 and 2 trials

Contact

  • 314-362-5817 (office)
  • 314-362-7086 (fax)
  • Division of Oncology
    Mail Stop 8056-0029-11
    Washington University
    660 South Euclid Avenue
    St. Louis, MO 63110
  • 11th Floor Mid-Campus Center (office)

Original Articles

  • Durvalumab Consolidation Should Be the Standard Therapy in Stage III EGFR-Mutant NSCLC After Chemoradiation
    Morgensztern D, Govindan R
    J Thorac Oncol 2021 Dec;16(12):1999-2001
  • Genomic Profiling of Lung Adenocarcinoma in Never-Smokers
    Devarakonda S, Li Y, Martins Rodrigues F, Sankararaman S, Kadara H, Goparaju C, Lanc I, Pepin K, Waqar SN, Morgensztern D, Ward J, Masood A, Fulton R, Fulton L, Gillette MA, Satpathy S, Carr SA, Wistuba I, Pass H, Wilson RK, Ding L, Govindan R
    J Clin Oncol 2021 Nov 20;39(33):3747-3758
  • Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients With Advanced Non-Small Cell Lung Carcinoma
    Camidge DR, Morgensztern D, Heist RS, Barve M, Vokes E, Goldman JW, Hong DS, Bauer TM, Strickler JH, Angevin E, Motwani M, Parikh A, Sun Z, Bach BA, Wu J, Komarnitsky PB, Kelly K
    Clin Cancer Res 2021 Nov 1;27(21):5781-5792
  • A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLC
    Hann CL, Burns TF, Dowlati A, Morgensztern D, Ward PJ, Koch MM, Chen C, Ludwig C, Patel M, Nimeiri H, Komarnitsky P, Camidge DR
    J Thorac Oncol 2021 Sep;16(9):1582-1588
  • A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC
    Malhotra J, Nikolinakos P, Leal T, Lehman J, Morgensztern D, Patel JD, Wrangle JM, Curigliano G, Greillier L, Johnson ML, Ready N, Robinet G, Lally S, Maag D, Valenzuela R, Blot V, Besse B
    J Thorac Oncol 2021 Sep;16(9):1559-1569
  • A Phase II Study of Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2 or STK11 Mutations
    Devarakonda S, Pellini B, Verghese L, Park H, Morgensztern D, Govindan R, Suresh R, Oppelt P, Baggstrom MQ, Wu N, Waqar SN
    J Thorac Dis 2021 Jul;13(7):4054-4062
  • Phase 1 Study Combining Alisertib With Nab-Paclitaxel in Patients With Advanced Solid Malignancies
    Lim KH, Opyrchal M, Acharya A, Boice N, Wu N, Gao F, Webster J, Lockhart AC, Waqar SN, Govindan R, Morgensztern D, Picus J, Tan BR, Baggstrom MQ, Maher CA, Wang-Gillam A
    Eur J Cancer 2021 Sep;154:102-110
  • Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451
    Owonikoko TK, Park K, Govindan R, Ready N, Reck M, Peters S, Dakhil SR, Navarro A, Rodriguez-Cid J, Schenker M, Lee JS, Gutierrez V, Percent I, Morgensztern D, Barrios CH, Greillier L, Baka S, Patel M, Lin WH, Selvaggi G, Baudelet C, Baden J, Pandya D, Doshi P, Kim HR
    J Clin Oncol 2021 Apr 20;39(12):1349-1359
  • NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021
    Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dowell J, Gettinger S, Gubens MA, Hegde A, Hennon M, Lackner RP, Lanuti M, Leal TA, Lin J, Loo BW Jr, Lovly CM, Martins RG, Massarelli E, Morgensztern D, Ng T, Otterson GA, Patel SP, Riely GJ, Schild SE, Shapiro TA, Singh AP, Stevenson J, Tam A, Yanagawa J, Yang SC, Gregory KM, Hughes M
    J Natl Compr Canc Netw 2021 Mar 2;19(3):254-266
  • Nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-Small Cell Lung Cancer (ABOUND.2L+)
    Morgensztern D, Dols MC, Ponce Aix S, Postmus PE, Bennouna J, Fischer JR, Juan-Vidal O, Stewart DJ, Ardizzoni A, Bhore R, Wolfsteiner M, Reck M, Talbot D, Govindan R, Ong TJ
    Front Oncol 2021 Feb 11;10:569715
  • A Phase I Trial of Temsirolimus and Erlotinib in Patients With Refractory Solid Tumors
    Park H, Williams K, Trikalinos NA, Larson S, Tan B, Waqar S, Suresh R, Morgensztern D, Van Tine BA, Govindan R, Luo J, Lockhart AC, Wang-Gillam A
    Cancer Chemother Pharmacol 2021 Mar;87(3):337-347
  • Nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis
    Langer CJ, Gajra A, Gridelli C, Konduri K, Morgensztern D, Spigel D, Talbot D, Thomas M, Weiss J, Pilot R, Bhore R, Wolfsteiner M, Ong TJ, Socinski M
    Front Oncol 2021 Jan 26;10:485587
  • Nanoparticle Albumin-Bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-Bound Paclitaxel Maintenance in Squamous Non-Small-Cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial
    Spigel DR, Jotte RM, Aix SP, Gressot L, Morgensztern D, McCleod M, Socinski MA, Daniel D, Juan-Vidal O, Mileham KF, West H, Page R, Reinmuth N, Knoble J, Chen T, Bhore R, Wolfsteiner M, Ong TJ, Gridelli C, Thomas M
    Clin Lung Cancer 2021 Jan;22(1):6-15e4
  • Mastering the Complex Targeted Therapy for Non-Small Cell Lung Cancer
    Devarakonda S, Govindan R, Morgensztern D
    Cancer Cell 2020 Sep 14;38(3):320-322
  • A Phase Ib Study of GSK3052230, an FGF Ligand Trap in Combination With Pemetrexed and Cisplatin in Patients With Malignant Pleural Mesothelioma
    van Brummelen EMJ, Levchenko E, Domine M, Fennell DA, Kindler HL, Viteri S, Gadgeel S, Lopez PG, Kostorov V, Morgensztern D, Orlov S, Zauderer MG, Vansteenkiste JF, Baker-Neblett K, Vasquez J, Wang X, Bellovin DI, Schellens JHM, Yan L, Mitrica I, DeYoung MP, Trigo J
    Invest New Drugs 2020 Apr;38(2):457-467
  • Nab-Paclitaxel in Older Patients With Non-Small Cell Lung Cancer Who Have Developed Disease Progression After Platinum-Based Doublet Chemotherapy
    Weiss JM, Pennell N, Deal AM, Morgensztern D, Bradford DS, Crane J, West HJ, Lee C, Pecot C, Stevenson JP, Irvin W, Socinski M, Stinchcombe T, Villaruz LC, Muss HB
    Cancer 2020 Mar 1;126(5):1060-1067
  • Effect of Metastatic Site on Survival in Patients With Neuroendocrine Neoplasms (NENs). An Analysis of SEER Data From 2010 to 2014
    Trikalinos NA, Tan BR, Amin M, Liu J, Govindan R, Morgensztern D
    BMC Endocr Disord 2020 Apr 3;20(1):44
  • Quality of Life With Second or Third Line Nab-Paclitaxel-Based Regimens in Advanced Non-Small-Cell Lung Cancer
    Ponce Aix S, Talbot D, Govindan R, Dols MC, Postmus PE, Lewanski C, Bennouna J, Fischer JR, Juan-Vidal O, Stewart DJ, Ardizzoni A, Bhore R, Wolfsteiner M, Reck M, Ong TJ, Morgensztern D
    Future Oncol 2020 Apr;16(12):749-762
  • SC-002 in Patients With Relapsed or Refractory Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma: Phase 1 Study
    Morgensztern D, Johnson M, Rudin CM, Rossi M, Lazarov M, Brickman D, Fong A
    Lung Cancer 2020 Jul;145:126-131
  • Phase 2 Study of the Focal Adhesion Kinase Inhibitor Defactinib (VS-6063) in Previously Treated Advanced KRAS Mutant Non-Small Cell Lung Cancer
    Gerber DE, Camidge DR, Morgensztern D, Cetnar J, Kelly RJ, Ramalingam SS, Spigel DR, Jeong W, Scaglioni PP, Zhang S, Li M, Weaver DT, Vaikus L, Keegan M, Horobin JC, Burns TF
    Lung Cancer 2020 Jan;139:60-67
  • Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients With DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study
    Morgensztern D, Besse B, Greillier L, Santana-Davila R, Ready N, Hann CL, Glisson BS, Farago AF, Dowlati A, Rudin CM, Moulec Le S, Lally S, Yalamanchili S, Wolf J, Govindan R, Carbone DP
    Clin Cancer Res 2019 Dec 1;25(23):6958-6966
  • An Open-Label Phase IB Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel, in FGFR1-Amplified Non-Small Cell Lung Cancer
    Morgensztern D, Karaseva N, Felip E, Delgado I, Burdaeva O, Domine M, Lara P, Paik PK, Lassen U, Orlov S, Trigo J, Shomova M, Baker-Neblett K, Vasquez J, Wang X, Yan L, Mitrica I, DeYoung MP, Garrido P
    Lung Cancer 2019 Oct;136:74-79
  • Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations
    Devarakonda S, Sankararaman S, Herzog BH, Gold KA, Waqar SN, Ward JP, Raymond VM, Lanman RB, Chaudhuri AA, Owonikoko TK, Li BT, Poirier JT, Rudin CM, Govindan R, Morgensztern D
    Clin Cancer Res 2019 Oct 15;25(20):6119-6126
  • RRx-001 Followed by Platinum Plus Etoposide in Patients With Previously Treated Small-Cell Lung Cancer
    Morgensztern D, Rose M, Waqar SN, Morris J, Ma PC, Reid T, Brzezniak CE, Zeman KG, Padmanabhan A, Hirth J, I Spira A, Trepel JB, Padda SK
    Br J Cancer 2019 Jul;121(3):211-217
  • Association Between Depth of Response and Survival in Patients With Advanced-Stage Non-Small Cell Lung Cancer Treated With First-Line Chemotherapy
    Morgensztern D, Ko A, O'Brien M, Ong TJ, Waqar SN, Socinski MA, Postmus PE, Bhore R
    Cancer 2019 Jul 15;125(14):2394-2399
  • A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105
    Drilon A, Fu S, Patel MR, Fakih M, Wang D, Olszanski AJ, Morgensztern D, Liu SV, Cho BC, Bazhenova L, Rodriguez CP, Doebele RC, Wozniak A, Reckamp KL, Seery T, Nikolinakos P, Hu Z, Oliver JW, Trone D, McArthur K, Patel R, Multani PS, Ahn MJ
    Cancer Discov 2019 Mar;9(3):384-395
  • First-In-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors
    Strickler JH, Weekes CD, Nemunaitis J, Ramanathan RK, Heist RS, Morgensztern D, Angevin E, Bauer TM, Yue H, Motwani M, Parikh A, Reilly EB, Afar D, Naumovski L, Kelly K
    J Clin Oncol 2018 Nov 20;36(33):3298-3306
  • Role of Immune Checkpoint Blockers in Patients With EGFR Mutation
    Ward J, Morgensztern D
    Transl Lung Cancer Res 2018 Dec;7(Suppl 4):S385-S387
  • Lorlatinib: A New-Generation Drug for ALK-Positive NSCLC
    Waqar SN, Morgensztern D
    Lancet Oncol 2018 Dec;19(12):1555-1557
  • Non-Small-Cell Lung Cancer With Brain Metastasis at Presentation
    Waqar SN, Samson PP, Robinson CG, Bradley J, Devarakonda S, Du L, Govindan R, Gao F, Puri V, Morgensztern D
    Clin Lung Cancer 2018 Jul;19(4):e373-e379
  • Recurrent WNT Pathway Alterations Are Frequent in Relapsed Small Cell Lung Cancer
    Wagner AH, Devarakonda S, Skidmore ZL, Krysiak K, Ramu A, Trani L, Kunisaki J, Masood A, Waqar SN, Spies NC, Morgensztern D, Waligorski J, Ponce J, Fulton RS, Maggi LB Jr, Weber JD, Watson MA, O'Conor CJ, Ritter JH, Olsen RR, Cheng H, Mukhopadhyay A, Can I, Cessna MH, Oliver TG, Mardis ER, Wilson RK, Griffith M, Griffith OL, Govindan R
    Nat Commun 2018 Sep 17;9(1):3787
  • ABOUND.2L+: A Randomized Phase 2 Study of Nanoparticle Albumin-Bound Paclitaxel With or Without CC-486 as Second-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
    Morgensztern D, Cobo M, Ponce Aix S, Postmus PE, Lewanski CR, Bennouna J, Fischer JR, Juan-Vidal O, Stewart DJ, Fasola G, Ardizzoni A, Bhore R, Wolfsteiner M, Talbot DC, Jin Ong T, Govindan R, On Behalf Of The Abound L Investigators
    Cancer 2018 Dec 15;124(24):4667-4675
  • NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018
    Kalemkerian GP, Loo BW Jr, Akerley W, Attia A, Bassetti M, Boumber Y, Decker R, Dobelbower MC, Dowlati A, Downey RJ, Florsheim C, Ganti AKP, Grecula JC, Gubens MA, Hann CL, Hayman JA, Heist RS, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran CA, Morgensztern D, Pokharel S, Portnoy DC, Rhodes D, Rusthoven C, Santana-Davila R, Williams CC Jr, Hoffmann KG, Hughes M
    J Natl Compr Canc Netw 2018 Oct;16(10):1171-1182
  • Early Mortality in Patients Undergoing Adjuvant Chemotherapy for Non-Small Cell Lung Cancer
    Morgensztern D, Samson PS, Waqar SN, Devarakonda S, Robinson CG, Govindan R, Puri V
    J Thorac Oncol 2018 Apr;13(4):543-549
  • The Biology and Management of Non-Small Cell Lung Cancer
    Herbst RS, Morgensztern D, Boshoff C
    Nature 2018 Jan 24;553(7689):446-454
  • Percutaneous Image-Guided Ablation in the Treatment of Osseous Metastases From Non-Small Cell Lung Cancer
    Ma Y, Wallace AN, Waqar SN, Morgensztern D, Madaelil TP, Tomasian A, Jennings JW
    Cardiovasc Intervent Radiol 2018 May;41(5):726-733
  • Immunogenicity of Influenza Vaccination in Patients With Cancer
    Waqar SN, Boehmer L, Morgensztern D, Wang-Gillam A, Sorscher S, Lawrence S, Gao F, Guebert K, Williams K, Govindan R
    Am J Clin Oncol 2018 Mar;41(3):248-253
  • Brain Metastases at Presentation in Patients With Non-Small Cell Lung Cancer
    Waqar SN, Waqar SH, Trinkaus K, Gadea CA, Robinson CG, Bradley J, Watson MA, Puri V, Govindan R, Morgensztern D
    Am J Clin Oncol 2018 Jan;41(1):36-40
  • Evolving Treatment Options for Lung Cancer
    Morgensztern D, Herbst RS
    Hematol Oncol Clin North Am 2017 Feb;31(1):xiii-xiv
  • Nothing but NET: A Review of Neuroendocrine Tumors and Carcinomas
    Oronsky B, Ma PC, Morgensztern D, Carter CA
    Neoplasia 2017 Dec;19(12):991-1002
  • Nab-Paclitaxel/Carboplatin Induction in Squamous NSCLC: Longitudinal Quality of Life While on Chemotherapy
    Thomas M, Spigel DR, Jotte RM, McCleod M, Socinski MA, Page RD, Gressot L, Knoble J, Juan O, Morgensztern D, Isla D, Kim ES, West H, Ko A, Ong TJ, Trunova N, Gridelli C
    Lung Cancer (Auckl) 2017 Oct 30;8:207-216
  • Treatment Advances in Small Cell Lung Cancer (SCLC)
    Waqar SN, Morgensztern D
    Pharmacol Ther 2017 Dec;180:16-23
  • Adjuvant Chemotherapy Is Associated With Improved Survival in Locally Invasive Node Negative Non-Small Cell Lung Cancer
    Ahmad U, Crabtree TD, Patel AP, Morgensztern D, Robinson CG, Krupnick AS, Kreisel D, Jones DR, Patterson GA, Meyers BF, Puri V
    Ann Thorac Surg 2017 Jul;104(1):303-307
  • Defining the Ideal Time Interval Between Planned Induction Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer
    Samson P, Crabtree TD, Robinson CG, Morgensztern D, Broderick S, Krupnick AS, Kreisel D, Patterson GA, Meyers B, Puri V
    Ann Thorac Surg 2017 Apr;103(4):1070-1075
  • Rovalpituzumab Tesirine, a DLL3-Targeted Antibody-Drug Conjugate, in Recurrent Small-Cell Lung Cancer: A First-In-Human, First-In-Class, Open-Label, Phase 1 Study
    Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, Byers LA, Johnson ML, Burris HA 3rd, Robert F, Han TH, Bheddah S, Theiss N, Watson S, Mathur D, Vennapusa B, Zayed H, Lally S, Strickland DK, Govindan R, Dylla SJ, Peng SL, Spigel DR
    SCRX16-001 investigators

    Lancet Oncol 2017 Jan;18(1):42-51
  • Immunotherapy in Lung Cancer
    Du L, Herbst RS, Morgensztern D
    Hematol Oncol Clin North Am 2017 Feb;31(1):131-141
  • Systemic Treatment of Brain Metastases
    Waqar SN, Morgensztern D, Govindan R
    Hematol Oncol Clin North Am 2017 Feb;31(1):157-176
  • Immune Checkpoint Inhibition in Patients With Brain Metastases
    Johanns T, Waqar SN, Morgensztern D
    Ann Transl Med 2016 Oct;4(Suppl 1):S9
  • Consolidation Chemotherapy Following Weekly Carboplatin-Paclitaxel Based Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer Is Associated With Improved Overall and Disease-Free Survival
    Weiner AA, Speirs CK, DeWees TA, Rehman S, Molotievschi A, Velez MA, Mullen D, Fergus S, Trovo M, Baggstrom MQ, Morgensztern D, Govindan R, Waqar SN, Bradley JD, Robinson CG
    Int J Radiat Oncol Biol Phys 2016 Oct 1;96(2S):E441-E442
  • Patterns of Care and Survival for Early Versus Delayed Radiation Therapy (RT) in Limited-Stage Small Cell Lung Cancer (LS-SCLC): A Review of the National Cancer Data Base
    Robinson CG, Samson P, Bradley JD, Roach MC, DeWees TA, Waqar SN, Baggstrom MQ, Govindan R, Higgins KA, Simone CB 2nd, Grover S, Puri V, Morgensztern D
    Int J Radiat Oncol Biol Phys 2016 Oct 1;96(2S):E436-E437
  • Role for Adjuvant Chemotherapy in Patients With Resected Small Cell Lung Cancer
    Du L, Waqar SN, Morgensztern D
    J Thorac Dis 2016 Aug;8(8):1891-2
  • Adjuvant Chemotherapy for Patients With T2N0M0 NSCLC
    Morgensztern D, Du L, Waqar SN, Patel A, Samson P, Devarakonda S, Gao F, Robinson CG, Bradley J, Baggstrom M, Masood A, Govindan R, Puri V
    J Thorac Oncol 2016 Oct;11(10):1729-35
  • Multimodality Therapy for NSCLC
    Du L, Waqar SN, Morgensztern D
    Cancer Treat Res 2016;170:151-63
  • Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer
    Morgensztern D, Herbst RS
    Clin Cancer Res 2016 Aug 1;22(15):3713-7
  • Precision Medicine in Lung Cancer: The Battle Continues
    Waqar SN, Morgensztern D
    J Thorac Dis 2016 Nov;8(11):2991-2993
  • Patterns of Care in Hilar Node-Positive (N1) Non-Small Cell Lung Cancer: A Missed Treatment Opportunity?
    Bott MJ, Patel AP, Verma V, Crabtree TD, Morgensztern D, Robinson CG, Colditz GA, Waqar S, Kreisel D, Krupnick AS, Patterson GA, Broderick S, Meyers BF, Puri V
    J Thorac Cardiovasc Surg 2016 Jun;151(6):1549-1558e2
  • Delayed Nausea and Vomiting From Carboplatin Doublet Chemotherapy
    Waqar SN, Mann J, Baggstrom MQ, Waqar MA, Chitneni P, Williams K, Gao F, Morgensztern D, Govindan R
    Acta Oncol 2016 Jun;55(6):700-4
  • A Phase I Trial of Temsirolimus and Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer
    Waqar SN, Baggstrom MQ, Morgensztern D, Williams K, Rigden C, Govindan R
    Chemotherapy 2016;61(3):144-7
  • The Role of Surgical Resection in Stage IIIa Non-Small Cell Lung Cancer: A Decision and Cost-Effectiveness Analysis
    Samson P, Patel A, Robinson CG, Morgensztern D, Chang SH, Colditz GA, Waqar S, Crabtree TD, Krupnick AS, Kreisel D, Patterson GA, Meyers BF, Puri V
    Ann Thorac Surg 2015 Dec;100(6):2026-2032
  • Multidisciplinary Treatment for Stage IIIa Non-Small Cell Lung Cancer: Does Institution Type Matter?
    Samson P, Patel A, Crabtree TD, Morgensztern D, Robinson CG, Colditz GA, Waqar S, Kreisel D, Krupnick AS, Patterson GA, Broderick S, Meyers BF, Puri V
    Ann Thorac Surg 2015 Nov;100(5):1773-9
  • EGFR Mutations in Non-Small-Cell Lung Cancer: Find, Divide, and Conquer
    Morgensztern D, Politi K, Herbst RS
    JAMA Oncol 2015 May 1;1(2):146-148
  • Chemotherapy for Advanced-Stage Non-Small Cell Lung Cancer
    Du L, Morgensztern D
    Cancer J 2015 Sep-Oct;21(5):366-370
  • Genomic Alterations in Lung Adenocarcinoma
    Devarakonda S, Morgensztern D, Govindan R
    Lancet Oncol 2015 Jul;16(7):e342-51
  • Treatment Outcomes in Stage I Lung Cancer: A Comparison of Surgery and Stereotactic Body Radiation Therapy
    Puri V, Crabtree TD, Bell JM, Broderick SR, Morgensztern D, Colditz GA, Kreisel D, Krupnick AS, Patterson GA, Meyers BF, Patel A, Robinson CG
    J Thorac Oncol 2015 Dec;10(12):1776-1784
  • MET Mutation Associated With Responsiveness to Crizotinib
    Waqar SN, Morgensztern D, Sehn J
    J Thorac Oncol 2015 May;10(5):e29-31
  • Immunotherapy for Non-Small Cell Lung Cancer: Are We on the Cusp of a New Era?
    Waqar SN, Morgensztern D
    Expert Rev Clin Immunol 2015 Aug;11(8):871-873
  • Role for Surgical Resection in the Multidisciplinary Treatment of Stage IIIB Non-Small Cell Lung Cancer
    Bott MJ, Patel AP, Crabtree TD, Morgensztern D, Robinson CG, Colditz GA, Waqar S, Kreisel D, Krupnicka AS, Patterson GA, Broderick S, Meyers BF, Puri V
    Ann Thorac Surg 2015 Jun;99(6):1921-1928
  • Postoperative Radiotherapy for Pathologic N2 Non-Small-Cell Lung Cancer Treated With Adjuvant Chemotherapy: A Review of the National Cancer Data Base
    Robinson CG, Patel AP, Bradley JD, DeWees T, Waqar SN, Morgensztern D, Baggstrom MQ, Govindan R, Bell JM, Guthrie TJ, Colditz GA, Crabtree TD, Kreisel D, Krupnick AS, Patterson GA, Meyers BF, Puri V
    J Clin Oncol 2015 Mar 10;33(8):870-6
  • Molecularly Targeted Therapies in Non-Small-Cell Lung Cancer Annual Update 2014
    Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R
    J Thorac Oncol 2015 Jan;10(1 Suppl 1):S1-S63
  • Clinical Next-Generation Sequencing in Patients With Non-Small Cell Lung Cancer
    Hagemann IS, Devarakonda S, Lockwood CM, Spencer DH, Guebert K, Bredemeyer AJ, Al-Kateb H, Nguyen TT, Duncavage EJ, Cottrell CE, Kulkarni S, Nagarajan R, Seibert K, Baggstrom M, Waqar SN, Pfeifer JD, Morgensztern D, Govindan R
    Cancer 2015 Feb 15;121(4):631-9
  • Central Nervous System Toxicities of Chemotherapeutic Agents
    Peddi PF, Peddi S, Santos ES, Morgensztern D
    Expert Rev Anticancer Ther 2014 Jul;14(7):857-863
  • National Patterns of Care and Outcomes After Combined Modality Therapy for Stage IIIA Non-Small-Cell Lung Cancer
    Patel AP, Crabtree TD, Bell JM, Guthrie TJ, Robinson CG, Morgensztern D, Colditz GA, Kreisel D, Krupnick AS, Bradley JD, Patterson GA, Meyers BF, Puri V
    J Thorac Oncol 2014 May;9(5):612-21
  • Treating Locally Advanced Disease: An Analysis of Very Large, Hilar Lymph Node Positive Non-Small Cell Lung Cancer Using the National Cancer Data Base
    Moreno AC, Morgensztern D, Boffa DJ, Decker RH, Yu JB, Detterbeck FC, Wang Z, Rose MG, Kim AW
    Ann Thorac Surg 2014 Apr;97(4):1149-55
  • Risk-Stratified Patients With Resectable Soft Tissue Sarcoma Benefit From Epirubicin-Based Adjuvant Chemotherapy
    Schenone AD, Luo J, Montgomery L, Morgensztern D, Adkins DR, Van Tine BA
    Cancer Med 2014 Jun;3(3):603-12
  • Summary Report From the 13th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting
    Morgensztern D, Govindan R
    Clin Lung Cancer 2014 Jan;15(1):16-20
  • Clinical Applications of the Cancer Genome Atlas Project (TCGA) for Squamous Cell Lung Carcinoma
    Devarakonda S, Morgensztern D, Govindan R
    Oncology (Williston Park) 2013 Sep;27(9):899-906
  • Genomic Landscape of Squamous Cell Carcinoma of the Lung
    Morgensztern D, Devarakonda S, Govindan R
    Am Soc Clin Oncol Educ Book 2013:348-53
  • Molecularly Targeted Therapies in Locally Advanced Non-Small-Cell Lung Cancer
    Devarakonda S, Morgensztern D, Govindan R
    Clin Lung Cancer 2013 Sep;14(5):467-72
  • Impact of Preoperative Radiation on Survival of Patients With T3N0 >7-Cm Non-Small Cell Lung Cancers Treated With Anatomic Resection Using the Surveillance, Epidemiology, and End Results Database
    Moreno AC, Morgensztern D, Yu JB, Boffa DJ, Decker RH, Detterbeck FC, Kim AW
    J Surg Res 2013 Sep;184(1):10-8
  • Evaluation of Novel Orthotopic Nude Mouse Models for Human Small-Cell Lung Cancer
    Isobe T, Onn A, Morgensztern D, Jacoby JJ, Wu W, Shintani T, Itasaka S, Shibuya K, Koo PJ, O'Reilly MS, Herbst RS
    J Thorac Oncol 2013 Feb;8(2):140-6
  • Use of New Treatment Modalities for Non-Small Cell Lung Cancer Care in the Medicare Population
    Vest MT, Herrin J, Soulos PR, Decker RH, Tanoue L, Michaud G, Kim AW, Detterbeck F, Morgensztern D, Gross CP
    Chest 2013 Feb 1;143(2):429-35
  • Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients With Metastatic Non-Small-Cell Lung Cancer
    Morgensztern D, Waqar S, Subramanian J, Trinkaus K, Govindan R
    J Thorac Oncol 2012 Oct;7(10):1485-9
  • Prognostic Significance of Tumor Size in Patients With Stage III Non-Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey From 1998 to 2003
    Morgensztern D, Waqar S, Subramanian J, Gao F, Trinkaus K, Govindan R
    J Thorac Oncol 2012 Oct;7(10):1479-84
  • Miscellaneous Agents
    Morgensztern D, Herbst RS
    J Thorac Oncol 2012 Dec;7(16 Suppl 5):S390-1
  • Multitargeted Tyrosine Kinase Inhibitors in Unselected Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC): Impressions From MONET (The Motesanib NSCLC Efficacy and Tolerability Study)
    Morgensztern D, Herbst RS
    J Clin Oncol 2012 Aug 10;30(23):2805-8
  • Thoroughness of Mediastinal Staging in Stage IIIA Non-Small Cell Lung Cancer
    Vest MT, Tanoue L, Soulos PR, Kim AW, Detterbeck F, Morgensztern D, Gross CP
    J Thorac Oncol 2012 Jan;7(1):188-95
  • Targeting Vascular Endothelial Growth Factor in Patients With Squamous Cell Lung Cancer
    Koo PJ, Morgensztern D, Boyer JL, Herbst RS
    J Clin Oncol 2012 Apr 1;30(10):1137-9
  • Waldenstrom Macroglobulinemia: A Surveillance, Epidemiology, and End Results Database Review From 1988 to 2005
    Sekhar J, Sanfilippo K, Zhang Q, Trinkaus K, Vij R, Morgensztern D
    Leuk Lymphoma 2012 Aug;53(8):1625-6
  • A Roundup of Articles Published in Recent Months
    Subramanian J, Waqar S, Morgensztern D, Govindan R
    J Thorac Oncol 2012 Mar;7(3):626-8
  • Recent Advances in Lung Cancer: Summary of Presentations From the 47 Th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2011
    Subramanian J, Waqar SN, Morgensztern D, Govindan R
    J Thorac Oncol 2012 Jan;7(1):260-5
  • Medullary Thyroid Cancer in the Past, Present and Future: From Bench to Bedside
    Desphande H, Morgensztern D, Sosa JA
    Expert Rev Endocrinol Metab 2011;6:585-97
  • A Roundup of Recently Published Articles Relevant to Thoracic Oncology
    Morgensztern D, Govindan R
    J Thorac Oncol 2011 Jul;6(7):1295-7
  • Summary of Presentations From the 46th Annual Meeting of the American Society of Clinical Oncology (2010): Focus on Developmental Therapeutics Related to Lung Cancer
    Morgensztern D, Pennell NA, Subramanian J, Govindan R
    Clin Lung Cancer 2011 Mar;12(2):94-9
  • Phase II Trial of S-1 as Second-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer
    Govindan R, Morgensztern D, Kommor MD, Herbst RS, Schaefer P, Gandhi J, Saito K, Zergebel C, Schiller J
    J Thorac Oncol 2011 Apr;6(4):790-5
  • Summary of Presentations From the 46th Annual Meeting of the American Society of Clinical Oncology (2010) Focus on Tumor Biology and Biomarkers Related to Lung Cancer
    Subramanian J, Corrales L, Soulieres D, Morgensztern D, Govindan R
    J Thorac Oncol 2011 Feb;6(2):399-403
  • Best of the Month: A Round Up of Articles Published in Recent Months
    Morgensztern D, Govindan R
    J Thorac Oncol 2011 Jan;6(1):223-6
  • Barriers to Enrollment in Non-Small Cell Lung Cancer Therapeutic Clinical Trials
    Baggstrom MQ, Waqar SN, Sezhiyan AK, Gilstrap E, Gao F, Morgensztern D, Govindan R
    J Thorac Oncol 2011 Jan;6(1):98-102
  • Lack of Survival Improvement in Patients With Peripheral T-Cell Lymphoma: A Surveillance, Epidemiology, and End Results Analysis
    Morgensztern D, Walker GR, Koniaris LG, Lossos IS
    Leuk Lymphoma 2011 Feb;52(2):194-204
  • Squamous Cell Cancer of the Head and Neck With Distant Metastasis at Presentation
    Kuperman DI, Auethavekiat V, Adkins DR, Nussenbaum B, Collins S, Boonchalermvichian C, Trinkaus K, Chen L, Morgensztern D
    Head Neck 2011 May;33(5):714-8
  • Vaccines and Immunotherapy for Non-Small Cell Lung Cancer
    Morgensztern D, Goodgame B, Govindan R
    J Thorac Oncol 2010 Dec;5(12 Suppl 6):S463-5
  • Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer
    Subramanian J, Morgensztern D, Govindan R
    Clin Lung Cancer 2010 Sep 1;11(5):311-9
  • Review of Ongoing Clinical Trials in Non-Small Cell Lung Cancer: A Status Report for 2009 From the ClinicalTrials.gov Website
    Subramanian J, Madadi AR, Dandona M, Williams K, Morgensztern D, Govindan R
    J Thorac Oncol 2010 Aug;5(8):1116-9
  • Best of the Month: A Roundup of Articles Published in Recent Months
    Morgensztern D, Govindan R
    J Thorac Oncol 2010 Aug;5(8):1305-7
  • Management of Patients With Advanced Non-Small Cell Lung Cancer: Role of Gefitinib
    Velcheti V, Morgensztern D, Govindan R
    Biologics 2010 May 25;4:83-90
  • High Rate and Prolonged Duration of Complete Remissions Induced by Rituximab, Methotrexate, Doxorubicin, Cyclophosphamide, Vincristine, Ifosfamide, Etoposide, Cytarabine, and Thalidomide (R-MACLO-IVAM-T), a Modification of the National Cancer Institute 89-C-41 Regimen, in Patients With Newly Diagnosed Mantle Cell Lymphoma
    Lossos IS, Hosein PJ, Morgensztern D, Coleman F, Escalon MP, Byrne GE Jr, Rosenblatt JD, Walker GR
    Leuk Lymphoma 2010 Mar;51(3):406-14
  • Trends in Stage Distribution for Patients With Non-Small Cell Lung Cancer: A National Cancer Database Survey
    Morgensztern D, Ng SH, Gao F, Govindan R
    J Thorac Oncol 2010 Jan;5(1):29-33
  • Distinctive Characteristics of Non-Small Cell Lung Cancer (NSCLC) in the Young: A Surveillance, Epidemiology, and End Results (SEER) Analysis
    Subramanian J, Morgensztern D, Goodgame B, Baggstrom MQ, Gao F, Piccirillo J, Govindan R
    J Thorac Oncol 2010 Jan;5(1):23-8
  • Primary Plasma Cell Leukemia: A Surveillance, Epidemiology, and End Results Database Analysis Between 1973 and 2004
    Ramsingh G, Mehan P, Luo J, Vij R, Morgensztern D
    Cancer 2009 Dec 15;115(24):5734-9
  • Novel Cytotoxic Agents
    Morgensztern D, Belani CP
    J Thorac Oncol 2009 Nov;4(11 Suppl 3):S1082-3
  • Improving Survival for Stage IV Non-Small Cell Lung Cancer: A Surveillance, Epidemiology, and End Results Survey From 1990 to 2005
    Morgensztern D, Waqar S, Subramanian J, Gao F, Govindan R
    J Thorac Oncol 2009 Dec;4(12):1524-9
  • A Phase I Study of Pegylated Liposomal Doxorubicin and Irinotecan in Patients With Solid Tumors
    Morgensztern D, Baggstrom MQ, Pillot G, Tan B, Fracasso P, Suresh R, Wildi J, Govindan R
    Chemotherapy 2009;55(6):441-5
  • Prognostic Factors Influencing Survival in Solitary Plasmacytoma
    Ramsingh G, Mehan P, Morgensztern D, Luo J, Vij R
    Br J Haematol 2009 May;145(4):540-2
  • Pulmonary Marginal Zone Lymphoma: A Single Centre Experience and Review of the SEER Database
    Stefanovic A, Morgensztern D, Fong T, Lossos IS
    Leuk Lymphoma 2008 Jul;49(7):1311-20
  • Adjuvant Chemotherapy for Lung Cancer: Cisplatin Doublets Only?
    Morgensztern D, Govindan R
    J Natl Compr Canc Netw 2008 Mar;6(3):277-84
  • EGFR Inhibitors as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
    Fong T, Morgensztern D, Govindan R
    J Thorac Oncol 2008 Mar;3(3):303-10
  • The Effect of FDG-PET on the Stage Distribution of Non-Small Cell Lung Cancer
    Morgensztern D, Goodgame B, Baggstrom MQ, Gao F, Govindan R
    J Thorac Oncol 2008 Feb;3(2):135-9
  • A Phase II Trial of Split, Low-Dose Docetaxel and Low-Dose Capecitabine: A Tolerable and Efficacious Regimen in the First-Line Treatment of Patients With HER2/Neu-Negative Metastatic Breast Cancer
    Silva O, Lopes G, Morgensztern D, Lobo C, Doliny P, Santos E, Abdullah S, Gautam U, Reis I, Welsh C, Slingerland J, Hurley J, Gluck S
    Clin Breast Cancer 2008 Apr;8(2):162-7
  • Augmentation of Anti-Tumor Responses of Adoptively Transferred CD8+T Cells in the Lymphopenic Setting by HSV Amplicon Transduction
    Nechushtan H, Pham D, Zhang Y, Morgensztern D, Yi KH, Shin SU, Federoff HJ, Bowers WJ, Tolba KA, Rosenblatt JD
    Cancer Immunol Immunother 2008 May;57(5):663-75
  • A Phase II Study of Topotecan and Docetaxel in Patients With Sensitive Relapse Small Cell Lung Cancer
    Morgensztern D, Perry MC, Govindan R
    Acta Oncol 2008;47(1):152-3
  • Treatment of Patients Excluded From Eastern Cooperative Oncology Group 4599 and AVAiL Studies: Focus on Brain Metastasis and Squamous Histology
    Morgensztern D, Govindan R
    Clin Lung Cancer 2008 Mar;9 Suppl 2:S57-61
  • Is There a Role for Cetuximab in Non Small Cell Lung Cancer?
    Morgensztern D, Govindan R
    Clin Cancer Res 2007 Aug 1;13(15 Pt 2):s4602-5
  • Rituximab for Treatment of Chemoimmunotherapy Naive Marginal Zone Lymphoma
    Lossos IS, Morgensztern D, Blaya M, Alencar A, Pereira D, Rosenblatt J
    Leuk Lymphoma 2007 Aug;48(8):1630-2
  • Second-Line Therapy for Esophageal Cancer
    Martin MG, Govindan R, Morgensztern D
    Expert Rev Anticancer Ther 2007 Jun;7(6):871-6
  • Gene Expression Profiling in Diffuse Large B-Cell Lymphoma
    Morgensztern D, Martin MG, Lossos IS
    Leuk Lymphoma 2007 Apr;48(4):669-82
  • Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database
    Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, Spitznagel EL, Piccirillo J
    J Clin Oncol 2006 Oct 1;24(28):4539-44
  • Clinical Trials of Antiangiogenic Therapy in Non-Small Cell Lung Cancer: Focus on Bevacizumab and ZD6474
    Morgensztern D, Govindan R
    Expert Rev Anticancer Ther 2006 Apr;6(4):545-51
  • Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma
    Lossos IS, Morgensztern D
    J Clin Oncol 2006 Feb 20;24(6):995-1007
  • PI3K/Akt/mTOR Pathway as a Target for Cancer Therapy
    Morgensztern D, McLeod HL
    Anticancer Drugs 2005 Sep;16(8):797-803
  • Molecular Prognostic Factors in Diffuse Large B-Cell Lymphoma
    Morgensztern D, Lossos IS
    Curr Treat Options Oncol 2005 Jul;6(4):269-77
  • Combination of Imatinib and Cytarabine for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
    Morgensztern D, Rosado MF, Raez LE, Santos ES, Cassileth PA
    Leuk Lymphoma 2005 Feb;46(2):297-8
  • Primary Lymphoblastic B-Cell Lymphoma of the Cranial Dura Mater: A Case Report and Review of the Literature
    Abdullah S, Morgensztern D, Rosado MF, Lossos IS
    Leuk Lymphoma 2005 Nov;46(11):1651-7
  • Prevalence of Hepatitis C Infection in Patients With Non-Hodgkin's Lymphoma in South Florida and Review of the Literature
    Morgensztern D, Rosado M, Silva O, Santos E, Abdullah S, Goodman M, Hamilton-Nelson K, Rosenblatt J, Lossos I
    Leuk Lymphoma 2004 Dec;45(12):2459-64
  • Non-Hodgkin's Lymphoma in the Microarray Era
    Lossos IS, Morgensztern D
    Clin Lymphoma 2004 Sep;5(2):128-9
  • Chronic Lymphocytic Leukemia-Associated Nephrotic Syndrome Caused by Focal Segmental Glomerulosclerosis
    Rosado MF, Morgensztern D, Abdullah S, Ruiz P, Lossos IS
    Am J Hematol 2004 Oct;77(2):205-6
  • Somatostatin Receptor Scintigraphy in MALT Lymphoma of the Lacrimal Gland Treated With Rituximab
    Morgensztern D, Rosado MF, Serafini AN, Lossos IS
    Leuk Lymphoma 2004 Jun;45(6):1275-8
  • Primary Diffuse Large Cell Lymphoma of the Mandible
    Rosado MF, Morgensztern D, Peleg M, Lossos IS
    Leuk Lymphoma 2004 May;45(5):1049-53
  • Heparin-Induced Thrombocytopenia Presenting With Thrombosis of Multiple Saphenous Vein Grafts and Myocardial Infarction
    Ayala E, Rosado MF, Morgensztern D, Kharfan-Dabaja MA, Byrnes JJ
    Am J Hematol 2004 Aug;76(4):383-5
  • Primary Hepatic Non-Hodgkin's Lymphomas: Case Report and Review of the Literature
    Santos ES, Raez LE, Salvatierra J, Morgensztern D, Shanmugan N, Neff GW
    Am J Gastroenterol 2003 Dec;98(12):2789-93
  • Acute Graft-Versus-Host Disease (AGVHD) Presenting With an Acquired Lupus Anticoagulant
    Kharfan-Dabaja MA, Morgensztern D, Santos E, Goodman M, Fernandez HF
    Bone Marrow Transplant 2003 Jan;31(2):129-31
  • Interleukin-2 and Rituximab in Lymphoma: Rationale and Current Trials
    Morgensztern D, Wolin M, Rosenblatt JD
    Biological Therapy of Lymphoma 2002;5:12-16
  • Warm-Antibody Autoimmune Hemolytic Anemia Developing After Thrombotic Thrombocytopenic Purpura
    Morgensztern D, Kharfan-Dabaja MA, Tsai HM, Lian EC
    Acta Haematol 2002;108(3):154-6

Book Chapters

  • Thoracic Cancers
    Herzog BH, Ellis H, Malik PS, Waqar SN, Devarakonda S, Govindan R, Morgensztern D
    In: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology Review, 5th Edition (Morgensztern D, Govindan R, Devarakonda S, Trikalinos NA, Editors), Wolters Kluwer, Philadelphia, 2022
  • Cancer of Unknown Primary Site
    Crees ZD, Morgensztern D
    In: The Washington Manual of Oncology, 4th Edition (Morgensztern D, Ghobadi A, Govindan R, Editors), Wolters Kluwer, Philadelphia, 2022
  • Thymoma and Mesothelioma
    Eulo VA, Flanagan ME, Morgensztern D
    In: The Washington Manual of Oncology, 4th Edition (Morgensztern D, Ghobadi A, Govindan R, Editors), Wolters Kluwer, Philadelphia, 2022
  • Non-Small Cell Lung Cancer
    Herzog BH, Morgensztern D, Waqar SN
    In: The Washington Manual of Oncology, 4th Edition (Morgensztern D, Ghobadi A, Govindan R, Editors), Wolters Kluwer, Philadelphia, 2022
  • Cancer
    Devarakonda S, Cashen A, Morgensztern D, Govindan R
    In: The Washington Manual of Medical Therapeutics, 36th Edition (Crees Z, Fritz C, Heudebert A, Noe J, Rengarajan A, Wang X, editors), Wolters-Kluwer, Philadelphia, 2020
  • Paraneoplastic syndromes
    Morgensztern D, Waqar SN, Govindan R
    In: Principles and Practice of Oncology, Lippincott Williams & Wilkins, 11th Edition, 2019
  • Cell-Free DNA in Cancer Diagnosis and Follow-Up
    Ferreira BP, Morgensztern D
    In: Cancer Genomics for the Clinician, 1st edition, Demos Medical, 2019
  • Cancer of the Lung
    Lu C, Morgensztern D, Chiang A, et al.
    In: Holland-Frei Cancer Medicine, 9th edition, 2017
  • Mutational Events in Lung Cancer: Present and Developing Technologies
    Morgensztern D, Devarakonda S, Govindan R
    In: IASLC Multidisciplinary Approach to Thoracic Oncology, 2017
  • Cancer
    Devarakonda S, Morgensztern D, Govindan R
    In: Washington Manual of Medical Therapeutics, 35th edition, 2016
  • Cancer Prevention
    Du L, Chen R, Morgensztern D, Aft R
    In: DeVita, Hellman and Rosenberg’s Cancer: Principles and Practice of Oncology Review. Lippincott, Williams and Wilkins, 4th edition, 2016
  • Genomics, Molecular Markers, and Targeted Therapies in Non-Small Cell Lung Cancer
    Morgensztern D, Herbst RS
    In: Adult Chest Surgery, 2nd edition, McGraw Hill, 2015
  • Thymoma and Mesothelioma
    Knoche E, Devarakonda S, Morgensztern D
    In: The Washington Manual of Oncology, 3rd edition, Lippincott-Williams and Wilkins, 2015
  • Kidney Cancer
    Morgensztern D, Roth B
    In: The Washington Manual of Oncology, 3rd edition, Lippincott-Williams and Wilkins, 2015
  • Bladder Cancer
    Morgensztern D, Roth B
    In: The Washington Manual of Oncology, 3rd edition, Lippincott-Williams and Wilkins, 2015
  • Testicular Cancer and Germ Cell Tumors
    Morgensztern D, Roth B
    In: The Washington Manual of Oncology, 3rd edition, Lippincott-Williams and Wilkins, 2015
  • Cancer of Unknown Primary Site
    Devarakonda S, Carpenter D, Morgensztern D
    In: The Washington Manual of Oncology, 3rd edition, Lippincott-Williams and Wilkins, 2015
  • Paraneoplastic Syndromes
    Govindan R, Stinchcombe T, Morgensztern D
    In: Principles and Practice of Oncology, Lippincott Williams and Wilkins, 10th Edition, 2015
  • Mutational Events in Lung Cancer: Present and Developing Technologies
    Morgensztern D, Mitsudomi T. Maher C, Govindan R
    In: IASLC Multidisciplinary Approach to Thoracic Oncology Textbook, 2014
  • Phase I Trials Today
    Morgensztern D, LoRusso P, Boerner SA, Herbst RS, Eder JP
    In: Mendelsohn's Molecular Basis of Cancer, Elsevier 4th Edition, 2014
  • Role of Next Generation Sequencing Technologies
    Devarakonda S, Morgensztern D, Govindan R
    In: Giaccone's Targeted Therapies in Oncology, CRC Press 2nd edition, 2014
  • Chemotherapy of Lung Cancer
    Waqar SN, Subramanian J, Morgensztern D, Rajagopalan K, Govindan R
    In: Chemotherapy Source Book, Lippincott-Williams and Wilkins, 5th edition, 2012
  • Cancer of the Testis
    Waqar SN, Morgensztern D, Roth B
    In: DeVita, Hellman and Rosenberg's Cancer: Principles and Practice of Oncology Review. Lippincott, Williams and Wilkins, 3rd edition, 2012
  • Cancer Prevention
    Morgensztern D, Auethavekiat V
    In: DeVita, Hellman and Rosenberg's Cancer: Principles and Practice of Oncology Review. Lippincott, Williams and Wilkins, 3rd edition, 2012
  • Oncology Emergencies
    Ramsingh G, Morgensztern D
    In: DeVita, Hellman and Rosenberg's Cancer: Principles and Practice of Oncology Review. Lippincott, Williams and Wilkins, 3rd edition, 2012
  • Cancer Therapy
    Goodgame B, Morgensztern D, Govindan R
    In: Washington Manual of Medicinal Therapeutics, 33rd edition, 2010
  • Lung Cancer
    Morgensztern D, Govindan R, Perry MC
    In: Hazzard's Geriatric Medicine and Gerontology, McGraw Hill, 6th edition, 2009
  • Cancer of the Testis
    Morgensztern D
    In: DeVita, Hellman and Rosenberg's Cancer: Principles and Practice of Oncology Review. Lippincott, Williams and Wilkins, 2nd edition, 2009
  • Cancer Prevention
    Morgensztern D, Auethavekiat V
    In: DeVita, Hellman and Rosenberg's Cancer: Principles and Practice of Oncology Review. Lippincott, Williams and Wilkins, 2nd edition, 2009
  • Oncology Emergencies
    Ramsingh G, Morgensztern D
    In: DeVita, Hellman and Rosenberg's Cancer: Principles and Practice of Oncology Review. Lippincott, Williams and Wilkins, 2nd edition, 2009
  • Lung Cancer: A Clinical Guide
    Morgensztern D, Govindan R (editors)
    Lippincott-Williams and Wilkins, 2008
  • Pulmonary Toxicity of Antineoplastic Therapy
    Morgensztern D, Govindan R
    In: Chemotherapy Source Book, Lippincott-Williams and Wilkins, 4th edition, 2008
  • Cancer of Unknown Primary
    Morgensztern D
    In: The Washington Manual of Oncology, 2nd edition, Lippincott-Williams and Wilkins, 2008
  • Thymoma and Mesothelioma
    Morgensztern D
    In: The Washington Manual of Oncology, 2nd edition, Lippincott-Williams and Wilkins, 2008
  • Testicular Cancer and Germ Cell Tumors
    Fong T, Morgensztern D
    In: The Washington Manual of Oncology, 2nd edition, Lippincott-Williams and Wilkins, 2008
  • Prostaglandins and COX 2: Role in Antiangiogenic Therapy
    Govindan R, Hennenfent K, Morgensztern D
    In: Antiangiogenic Cancer Therapy, 2007
  • Prognostic Factors in Diffuse Large B Cell Lymphoma: Present and Future
    Lossos IS, Morgensztern D
    In: ASCO Educational Book, 2007
  • Management of Locally Advanced NSCLC: Case Studies
    Morgensztern D, Govindan R
    In: Recent Advances in Non-Small-Cell Lung Cancer. CMP Medica, 2nd edition, 2006
  • Epidemiology of Breast Cancer
    Morgensztern D, Rosado MF
    In: Silva and Zurida's Breast Cancer: a Practical Guide. Elsevier, 3rd edition, 2006
  • Pathology of Breast Cancer
    Morgensztern D, Jorda M
    In: Silva and Zurida's Breast Cancer: a Practical Guide. Elsevier, 3rd edition, 2006
  • Testicular Cancer
    Morgensztern D, Tan B
    In: DeVita, Hellman and Rosenberg's Cancer: Principles and Practice of Oncology Review. Lippincott, Williams and Wilkins, 1st edition, 2005